RxDoctor Payments Data

Brady Walker, MD

Urology · Springfield, ORNPI 1346300530

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (49.8%), travel and lodging and education — rather than concentrated in one kind of arrangement. Urogpo LLC accounts for 75.9% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $2,472 and has fallen 94.7% since, to $131 in 2025.

$2,814in general payments, 2019–2025

Across 44 payments — averaging $63.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Urogpo LLC$2K
  • Johnson & Johnson$295
  • Sumitomo Pharma America, Inc.$60
  • Tolmar, Inc.$60
  • AbbVie$45
  • Astellas Pharma US Inc$39
  • plus $179 from 9 others

What the payments were for

  • Travel & lodging$1,36148%
  • Food & beverage$1,40250%
  • Education$512%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,814 in reported general payments places this provider in the 60th percentile of 153 urology providers in Oregon.

See all urology providers in Oregon

Medicare billing

Part B allowed, 2024
$143,498
Medicare patients
395
Services billed
3,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide43$568,036
ErleadaApalutamide29$425,922
XtandiEnzalutamide19$261,588
YonsaAbiraterone Acet,submicronized12$124,903
ZytigaAbiraterone Acetate12$118,177
MyrbetriqMirabegron106$84,311
GemtesaVibegron39$21,225
Tamsulosin Hcl611$10,938
Testosterone45$8,560
Solifenacin Succinate146$4,624
Finasteride279$3,950
Testosterone Cypionate68$3,144
Methenamine Hippurate31$2,640
Trimethoprim27$2,231
Abiraterone Acetate15$1,972

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$22$568,03643 claims
Johnson & JohnsonErleada, Zytiga$295$544,09841 claims
Astellas Pharma US IncXtandi, Myrbetriq$39$345,899125 claims
Sumitomo Pharma America, Inc.Gemtesa$60$21,22539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 153 urology providers in Oregon.

Other urology in Springfield

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →